of novel techniques such as LDpred and MTAG may increase their precision and allow for their application in smaller samples (Vilhjalmsson et al., 2015, Turley et al., 2017). Regardless, research using smaller samples should consider the possibility of false positive and/or negative results. Fourth, PRS can be extremely useful within general population samples. Indeed, the consequences of medication and disease expression are an important confound for identifying factors that confer disease risk, especially for severe conditions such as schizophrenia. By using PRS as tools to uncover genetically-driven individual differences in mechanistic phenotypes, the field can combat confounds of medication and disease expression. Fifth, unlike other measures of cumulative genomic influence (e.g., SNP-h2), PRS approaches can be generalized and applied across samples. For these reasons, PRS have accelerated the incorporation of genomically-informed analyses into various clinical psychology subspecialties.
